Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Illumina Rose 15.3% in January

By Billy Duberstein - Feb 8, 2021 at 8:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genomics leader got a boost from identifying new COVID variants, and won a patent lawsuit.

What happened

Shares of genomics leader Illumina (ILMN 0.08%) rose 15.3% in January, according to data provided by S&P Global Market Intelligence. Although the genomics leader didn't announce any financial updates during the month, it did win a patent lawsuit.

Furthermore, the identification of new COVID-19 variants overseas using genomics testing drew attention to the importance of genomics overall. The U.S. hadn't used genomics as much, so putting a spotlight on COVID-19 gene sequencing gave another boost to this industry leader.

A DNA strand illuminated.

Image source: Getty Images.

So what

On Jan. 20, the High Court of Justice, Chancery Division, in the U.K. ruled that BGI Genomics, a Hong Kong company, violated Illumina's patents on gene sequencing chemistry. This U.K. ruling followed other similar wins for Illumina at patent courts in the U.S., Germany, Spain, Finland, and Sweden. Other patent lawsuits against BGI are ongoing in Hong Kong, France, Belgium, Denmark, Switzerland, Turkey, and Italy.

Aside from the positive patent ruling, the identification of new and more dangerous COVID-19 variants in the U.K. through the use of genomic testing shone a light on the benefits of genomics and its underutilization in the U.S. While the U.K. sequences about 10% of all COVID samples, which led the country to discover the more infectious strain, the U.S. had only sequenced about 0.3% of all COVID samples.

In response, President Biden advocated for more genomic surveillance of COVID strains in the U.S. in order to track outbreaks and new mutations, adding genomics funding to the proposed $1.9 trillion American Rescue Plan.

The prospect of more hospitals and research institutions using genomics to track COVID variants would likely mean a boost in revenue for Illumina, the leader in the space.

Now what

It was a great month for Illumina, but we are still very likely in the early innings of genomics testing for a wide range of applications, including cancer, COVID and other viruses, and pre-natal testing. Illumina's results dipped in 2020, as researchers stayed home and hospitals didn't do as much genetic testing other than for COVID, but they should rebound this year.

This leading biotech company is also looking forward to closing its $8 billion proposed acquisition of GRAIL, which uses genomics for liquid biopsies in cancer screening. Another update should be forthcoming on Feb. 11, when Illumina reports its fourth-quarter results.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$233.74 (0.08%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.